Miguel Zubizarreta, CEO, and Robert Arch, President of Immunophotonics, Inc. are gearing up for a presentation with exciting updates at the BIO Investment & Growth Summit, taking place March 2–3, 2026, at the Eden Roc Miami Beach Hotel. Miguel and Robert look forward to connecting with investors and industry peers as they showcase Immunophotonics’ pioneering efforts in Interventional Immuno‑Oncology® with focus on our lead...
Immunophotonics is excited to announce that the European Patent Office has issued a new patent titled “Semi-Synthetic Biopolymers for Use in Stimulating the Immune System.” This patent, which provides Immunophotonics with exclusivity extending into 2039 for this use, is now valid in over 20 European countries and covers the use of our lead drug candidate, IP‑001, in combination with checkpoint inhibitors for the treatment of...
Immunophotonics is attending SIO Scientific Meeting in Savannah, Georgia. Our President, Robert Arch, PhD, and CIO & Co-Founder, Tomas Hode, PhD, will share updates on IP-001, an intratumoral immunotherapy designed to activate the patient’s immune system following ablation, with the goal of reducing recurrence risk while preserving the current standard of care. If you are...
Immunophotonics’ CIO, Tomas Hode, PhD, is attending the Spectrum Conference, January 15–17, in Miami, Florida. This event brings together some of the most talented minds in interventional oncology, and Tomas looks forward to connecting, sharing ideas, and learning about the latest advancements in interventional therapeutics. These insights will help us advance clinical trials of IP-001,...
Our networking is in full swing for JPM2026! We invite you to meet our team at the 2026 Annual Summit in San Francisco, January 11 -15, 2026. Robert Arch at JPM Biotech Showcase and Sachs Oncology Innovation Forum; Miguel Zubizarreta and Theresa Visarius at BIO Partnering. Meeting with our team members in San Francisco will...
We are excited to welcome Richard Levenson, M.D. to further strengthen our leadership team as a member of the Board of Directors of Immunophotonics, Inc. Dr. Levenson is a Professor of Pathology at UC Davis, internationally recognized for his pioneering work in medical imaging, cancer diagnostics, and translational research. His career spans academia and industry. His innovations in multispectral imaging,...
Tomas Hode, PhD (Chief Innovation Officer) and Robert Arch, PhD (President) will be representing Immunophotonics at the 8th Biannual AngioDynamics International Life Symposium in Monte Carlo, taking place November 6–8, 2025. This prestigious event brings together leaders and innovators in vascular health, oncology, and medical technology to explore cutting-edge advancements and foster meaningful collaboration. They...
Robert Arch, PhD (President) will be attending BIO-Europe 2025 in Vienna, Austria, November 3-5. As one of the premier partnering conferences for the global biotech industry, BIO-Europe offers a unique opportunity to connect, collaborate, and explore the future of life sciences innovation. He is looking forward to an inspiring few days at BIO-Europe. If you’re...
Robert Arch, PhD (President) at Immunophotonics will be attending the ThinkEquity Conference at the Mandarin Oriental, New York on October 30th. Robert will be presenting at 12:00 PM – 12:30 PM in the Lotus Suite West Don’t miss his talk on how Immunophotonics’ innovative Interventional Immuno-Oncology® platform is redefining what’s possible in preventing tumor recurrence after local ablation therapy....
Immunophotonics is excited to be part of the Life Sciences Innovation Forum 2025 in Riyadh! Hosted by J.P. Morgan Asset Management in collaboration with KAIMRC, this two-day event is a powerful convergence of biotech pioneers, global investors, and healthcare innovators. From groundbreaking panels on biomanufacturing, precision medicine, and clinical trials leadership, to startup pitches and...
